A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma

European Journal of Ophthalmology

Volumn 18, Issue 5, 2008, Pages 778-786

  Hommer, A ^a   Thygesen, J ^b   Ferreras, A ^c   Wickstrøm, Jannie ^d   Friis, M M ^d   Buchholz, P ^e   Walt, J G ^f  

^a Krankenanstalt Sanatorium Hera   (Austria)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d MUUSMANN Research and Consulting   (Denmark)

^e AIlergan R and D Europe   (Germany)

^f ALLERGAN INC   (United States)

Author keywords

Brimonidine; Cost effectiveness; Drug combinations; Glaucoma; Primary open angle glaucoma

Indexed keywords

BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; TIMOLOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FINLAND; FRANCE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; SWEDEN; SWITZERLAND; TREATMENT DURATION; UNITED KINGDOM;

EID: 54349105427     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800519     Document Type: Article

References (20)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-93.
2. Infeld DA, O'Shea JG. Glaucoma: diagnosis and management. Postgrad Med J 1998; 74: 709-15.
3. Tuck MW, Crick RP. The projected increase in glaucoma due to an ageing population. Ophthalmic Physiol Opt 2003; 23: 175-9.
4. Anton A, Andrada MT, Mujica V, Calle MA, Portela J, Mayo A. Prevalence of primary open angle glaucoma in a Spanish population: the Segovia study. J Glaucoma 2004; 13: 371-6.
5. Tuck MW, Crick RP. The age distribution of primary open angle glaucoma. Ophthalmic Epidemiol 1998; 5: 173-83.
6. Berleen G. A healthier elderly population in Sweden. National Institute of Public Health, 2004.
7. Tuulonen A, Airaksinen PJ, Erola E, et al. The Finnish evidencebased guideline for openangle glaucoma. Acta Ophthalmol Scand 2003; 81: 3-18.
8. Kass MA, Gordon MO. Intraocular pressure and visual field progression in open-angle glaucoma. Am J Ophthalmol 2000; 130: 490-1.
9. Suzuki Y, Shirato S, Adachi M, Hamada C. Risk factor for the progression of treated primary open-angle glaucoma: a multivariate life-table analysis. Graefes Arch Clin Exp Ophthalmol 1999; 237: 463-7.
10. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 2nd ed. Savona, Italy: Editrice DOGMA s.r.l., 2003; 3-3-3-45.
11. The AGIS Investigators. The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. Arch Ophthalmol 2000; 118: 1639-52.
12. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
13. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
14. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13.
15. Kobelt G. Comparative data for all countries. In: Jönsson B, Krieglstein G, eds. Primary open-angle glaucoma. Differences in international treatment patterns and costs. Oxford, England: ISIS Medical Media, 1998; 116-26.
16. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six month comparison of efficacy and tolerability. Ophthalmology 2003; 110: 615-24.
17. Solish AM, DeLucca PT, Cassel DA, Kolodny AH, Hustad CM, Skobieranda F. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004; 13: 149-57.
18. Goni F; Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma an ocular hypertension. Eur J Ophthalmol 2005; 15: 581-90.
19. Simmons S; Alphagan®/Trusopt® Study Group. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001; 23: 604-19.
20. Arcieri ES, Arcieri RS, Pereira AC, Andreo FG, Finotti IG, Sá Filho WF. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 2007; 23: 683-9.